Intellicell Biosciences Inc (fka SVFC)

[Nadendla]

The company's (SVFC) expansion plan is to acquire cash flow positive ambulatory surgery centers in major US markets beginning in 2013 with a target of operating 20 centers by 2016. Each center will generate between $10M to $30M of revenue per annum in traditional surgical procedures such as orthopedics, aesthetic plastic surgery, urology, etc.
IntelliCell will place a cGTP compliant cellular processing laboratory in each surgical facility and offer regenerative medical procedures in addition to the surgical procedures. The company believes an additional $10M to $15M can be generated per annum from the cellular therapies at an average gross profit of 70% from the cellular procedures.
The financial model target is to reach over $600m in combined revenues by 2018

http://proactivecapital.com/wp-content/uploads/2013/02/imtellicellfactsheet.pdf

...AWESOME!!....This needs to be added..Great DD Traderboy1966!..

SVFC